Zhiguo Wu

List of Publications by Year
in descending order

43 papers	1,201 citations	304743 22 h-index	377865 34 g-index
43 all docs	43 docs citations	43 times ranked	2216 citing authors

#	Article	IF	Citations
1	A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression. Psychopharmacology, 2014, 231, 685-693.	3.1	65
2	Dissociated large-scale functional connectivity networks of the precuneus in medication-naïve first-episode depression. Psychiatry Research - Neuroimaging, 2015, 232, 250-256.	1.8	65
3	Ratio of mBDNF to proBDNF for Differential Diagnosis of Major Depressive Disorder and Bipolar Depression. Molecular Neurobiology, 2017, 54, 5573-5582.	4.0	62
4	Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: A report of OPERATION study. Journal of Affective Disorders, 2013, 150, 834-839.	4.1	58
5	Brain-derived neurotrophic factor levels and bipolar disorder in patients in their first depressive episode: 3-year prospective longitudinal study. British Journal of Psychiatry, 2014, 205, 29-35.	2.8	54
6	Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive–compulsive symptoms. Psychopharmacology, 2013, 230, 49-55.	3.1	53
7	Comorbidity of depressive and anxiety disorders: challenges in diagnosis and assessment. Shanghai Archives of Psychiatry, 2014, 26, 227-31.	0.7	53
8	Identification of plasma biomarkers for distinguishing bipolar depression from major depressive disorder by iTRAQ-coupled LC–MS/MS and bioinformatics analysis. Psychoneuroendocrinology, 2017, 86, 17-24.	2.7	51
9	IL-23 and TGF-β1 levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode. Journal of Affective Disorders, 2015, 174, 361-366.	4.1	50
10	Comparisons of the Efficacy and Tolerability of Extended-Release Venlafaxine, Mirtazapine, and Paroxetine in Treatment-Resistant Depression. Journal of Clinical Psychopharmacology, 2010, 30, 357-364.	1.4	48
11	A Pilot Study of the Efficacy and Safety of Paroxetine Augmented With Risperidone, Valproate, Buspirone, Trazodone, or Thyroid Hormone in Adult Chinese Patients With Treatment-Resistant Major Depression. Journal of Clinical Psychopharmacology, 2011, 31, 638-642.	1.4	47
12	Different levels of pro- and anti-inflammatory cytokines in patients with unipolar and bipolar depression. Journal of Affective Disorders, 2018, 237, 65-72.	4.1	47
13	Lack of effect of brain derived neurotrophic factor (BDNF) Val66Met polymorphism on early onset schizophrenia in Chinese Han population. Brain Research, 2011, 1417, 146-150.	2.2	42
14	Prevalence, risk factors and clinical characteristics of suicidal ideation in Chinese patients with depression. Journal of Affective Disorders, 2018, 235, 135-141.	4.1	40
15	Number and characteristics of medical professionals working in Chinese mental health facilities. Shanghai Archives of Psychiatry, 2013, 25, 277-85.	0.7	39
16	Somatic symptoms vary in major depressive disorder in China. Comprehensive Psychiatry, 2018, 87, 32-37.	3.1	37
17	Association Study of Val66Met Polymorphism in Brain-Derived Neurotrophic Factor Gene with Clozapine-Induced Metabolic Syndrome: Preliminary Results. PLoS ONE, 2013, 8, e72652.	2.5	36
18	Identification of IL6 as a susceptibility gene for major depressive disorder. Scientific Reports, 2016, 6, 31264.	3.3	35

#	Article	IF	Citations
19	Significantly decreased mRNA levels of BDNF and MEK1 genes in treatment-resistant depression. NeuroReport, 2014, 25, 753-755.	1.2	32
20	The association between somatic symptoms and suicidal ideation in Chinese first-episode major depressive disorder. Journal of Affective Disorders, 2019, 245, 17-21.	4.1	30
21	Association of genetic variation in CACNA1C with bipolar disorder in Han Chinese. Journal of Affective Disorders, 2013, 150, 261-265.	4.1	27
22	Influence of BCL2 gene in major depression susceptibility and antidepressant treatment outcome. Journal of Affective Disorders, 2014, 155, 288-294.	4.1	27
23	Causes of drug discontinuation in patients with major depressive disorder in China. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 96, 109755.	4.8	23
24	ZNF804A Genetic Variation Confers Risk to Bipolar Disorder. Molecular Neurobiology, 2016, 53, 2936-2943.	4.0	21
25	Reduced ENA78 levels as novel biomarker for major depressive disorder and venlafaxine efficiency: Result from a prospective longitudinal study. Psychoneuroendocrinology, 2017, 81, 113-121.	2.7	21
26	The clinical correlates of comorbid anxiety symptoms and syndromal anxiety in patients with major depressive disorder. Psychiatry Research, 2018, 269, 251-257.	3.3	18
27	A haplotype in the 5'-upstream region of the NDUFV2 gene is associated with major depressive disorder in Han Chinese. Journal of Affective Disorders, 2016, 190, 329-332.	4.1	13
28	Clinical features of the patients with major depressive disorder co-occurring insomnia and hypersomnia symptoms: a report of NSSD study. Sleep Medicine, 2021, 81, 375-381.	1.6	13
29	Subtypes of treatment-resistant depression determined by a latent class analysis in a Chinese clinical population. Journal of Affective Disorders, 2019, 249, 82-89.	4.1	12
30	Guidelines Disconcordance in Acute Bipolar Depression: Data from the National Bipolar Mania Pathway Survey (BIPAS) in Mainland China. PLoS ONE, 2014, 9, e96096.	2.5	11
31	Evaluating the association between the SHANK3 gene and bipolar disorder. Psychiatry Research, 2016, 244, 284-288.	3.3	10
32	Disagreement and factors between symptom on self-report and clinician rating of major depressive disorder: A report of a national survey in China. Journal of Affective Disorders, 2019, 253, 141-146.	4.1	10
33	Validation of the Chinese Version of the Short TEMPS-A and its application in patients with mood disorders. Journal of Affective Disorders, 2015, 170, 178-184.	4.1	9
34	Symptomatology differences of major depression in psychiatric versus general hospitals: A machine learning approach. Journal of Affective Disorders, 2020, 260, 349-360.	4.1	7
35	Down-regulation of PRKCB1 expression in Han Chinese patients with subsyndromal symptomatic depression. Journal of Psychiatric Research, 2015, 69, 1-6.	3.1	6
36	Guidelines concordance of maintenance treatment in euthymic patients with bipolar disorder: Data from the national bipolar mania pathway survey (BIPAS) in mainland China. Journal of Affective Disorders, 2015, 182, 101-105.	4.1	6

#	Article	IF	Citations
37	Association analysis between mitogen-activated protein/extracellular signal-regulated kinase (MEK) gene polymorphisms and depressive disorder in the Han Chinese population. Journal of Affective Disorders, 2017, 222, 120-125.	4.1	6
38	Predictors and moderators of quality of life in patients with major depressive disorder: An AGTs-MDD study report. Journal of Psychiatric Research, 2021, 138, 96-102.	3.1	5
39	Advance in Diagnosis of Depressive Disorder. Advances in Experimental Medicine and Biology, 2019, 1180, 179-191.	1.6	4
40	Difference in the regulation of biological rhythm symptoms of Major depressive disorder between escitalopram and mirtazapine. Journal of Affective Disorders, 2022, 296, 258-264.	4.1	3
41	Lower Health Literacy of Mania Than Depression Among Older People: A Random Survey of a Community Healthcare Service Center. Frontiers in Psychiatry, 2021, 12, 512689.	2.6	2
42	Schizophrenia, bipolar disorder, or intracranial aneurysm? A case report. Brain and Behavior, 2021, 11, e2245.	2.2	2
43	Evaluating the efficacy and moderators of algorithm-guided antidepressant treatments of major depressive disorder. Journal of Affective Disorders, 2022, 297, 68-75.	4.1	1